Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.

MLA

Baek, Jin Ho, et al. “Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutated Non-Small Cell Lung Cancer except Both Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in Korea.” Lung Cancer (Amsterdam, Netherlands), vol. 87, no. 2, Feb. 2015, pp. 148–54. EBSCOhost, https://doi.org/10.1016/j.lungcan.2014.11.013.

APA

Baek, J. H., Sun, J.-M., Min, Y. J., Cho, E. K., Cho, B. C., Kim, J.-H., Ahn, M.-J., & Park, K. (2015). Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. Lung Cancer (Amsterdam, Netherlands), 87(2), 148–154. https://doi.org/10.1016/j.lungcan.2014.11.013

Chicago

Baek, Jin Ho, Jong-Mu Sun, Young Joo Min, Eun Kyung Cho, Byoung Chul Cho, Joo-Hang Kim, Myung-Ju Ahn, and Keunchil Park. 2015. “Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutated Non-Small Cell Lung Cancer except Both Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in Korea.” Lung Cancer (Amsterdam, Netherlands) 87 (2): 148–54. doi:10.1016/j.lungcan.2014.11.013.